Abstract Brain metastases affect up to 30% of patients with metastatic cancer and are a major cause for morbidity and mortality. Treatment approaches include neurosurgery, various approaches to radiotherapy and systemic pharmacotherapy. Encouraging response rates have been observed in patients with melanoma and non-small cell lung cancer (NSCLC) with asymptomatic or oligo-symptomatic brain metastases treated with novel systemic therapies, including immune checkpoint inhibitors and targeted therapy, challenging the need for immediate radiosurgery. Eligible patients for STRIKE must have newly diagnosed and untreated asymptomatic or oligo-symptomatic brain metastases from melanoma or NSCLC, with an indication for systemic therapy. The treatment regimen consists of standard systemic treatment with (Arm A) or without (Arm B) stereotactic radiosurgery. Systemic therapy follows the current standard of care according to the primary tumor. Primary endpoint is CNS-specific progression-free survival (PFS), locally assessed according to RANO criteria. Secondary endpoints include CNS-specific PFS per tumour cohort, objective CNS response rate, duration of CNS response, pattern of CNS-specific progression, extra-CNS progression, incidence of radionecrosis and pseudoprogression, overall survival, neurocognitive function, quality of life and functional independence, and toxicity. We assume that the addition of radiosurgery to systemic treatment will increase median CNS-specific PFS by 62% from a median of 4 and 8 months for melanoma and NSCLC, respectively, corresponding to an overall hazard ratio of 0.62 for time to CNS failure. According to the log-rank test, at a 5% one-sided significance level, 143 events provide 88% power for a sample size of 180 patients. The USZ-STRIKE trial is an academic study sponsored by ETOP IBCSG Partners Foundation, with substantial funding from the USZ Foundation. The trial is being conducted in 15 centres in Switzerland, Italy, the Netherlands, Spain and the United Kingdom. Current accrual is 57 patients. he study is registered on ClinicalTrials.gov: NCT05522660.

This randomized clinical trial evaluates the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous non-small cell lung cancer. QuestionCan treatment with the combination of tiragolumab plus atezolizumab plus chemotherapy improve outcomes for patients with advanced nonsquamous non-small cell lung cancer (NSCLC)?FindingsIn this phase 3 randomized clinical trial of 542 patients with previously untreated, locally advanced unresectable or metastatic NSCLC, tiragolumab plus atezolizumab plus chemotherapy did not demonstrate a progression-free or overall survival benefit vs placebo plus pembrolizumab plus chemotherapy. Tiragolumab plus atezolizumab plus chemotherapy demonstrated a safety profile that was generally similar to that of pembrolizumab plus chemotherapy.MeaningTreatment with the combination of tiragolumab plus atezolizumab plus chemotherapy did not improve outcomes for patients with advanced nonsquamous NSCLC compared with pembrolizumab plus chemotherapy. ImportanceProgrammed cell death 1 ligand 1/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, survival benefit is limited, and many patients experience disease progression.ObjectiveTo evaluate the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC.Design, Setting, and ParticipantsSKYSCRAPER-06 was a phase 3 randomized clinical trial that recruited patients with previously untreated, locally advanced unresectable or metastatic NSCLC at 129 sites in 21 countries between December 15, 2020, and September 14, 2023 (data cutoff, April 19, 2024).InterventionPatients were randomized 1:1 to receive either tiragolumab, 600 mg, plus atezolizumab, 1200 mg, plus chemotherapy (pemetrexed, 500 mg/m2, and carboplatin [area under the curve 5], or cisplatin, 75 mg/m2) or placebo plus pembrolizumab, 200 mg, plus chemotherapy via intravenous infusion on day 1 of each 21-day cycle until disease progression, loss of clinical benefit, unacceptable toxic effect, or withdrawal of consent.Main Outcomes and MeasuresPrimary end points were investigator-assessed progression-free survival and overall survival. The safety and tolerability of the study drugs were also evaluated.ResultsOf 542 patients in the full analysis set (mean [SD] age, 63.6 [9.3] years; 353 [65.1%] male), 269 were randomized to tiragolumab plus atezolizumab plus chemotherapy and 273 to placebo plus pembrolizumab plus chemotherapy. Overall, baseline demographics were similar between treatment groups. At data cutoff (median follow-up, 11.8 months), median investigator-assessed progression-free survival was 8.3 months (95% CI, 7.1-9.6 months) with tiragolumab plus atezolizumab plus chemotherapy vs 9.9 months (95% CI, 8.7-11.9 months) with placebo plus pembrolizumab plus chemotherapy (hazard ratio, 1.27; 95% CI, 1.02-1.57; P = .99); median overall survival was 18.9 months (95% CI, 15.2-23.8 months) vs 23.1 months (95% CI, 20.7-33.0 months) in each treatment group, respectively (hazard ratio, 1.33; 95% CI, 1.02-1.73; P = .98). Grade 3 to 4 adverse events occurred in 164 of 267 patients (61.4%) in the tiragolumab plus atezolizumab plus chemotherapy group and 165 of 272 patients (60.7%) in the placebo plus pembrolizumab plus chemotherapy group, with grade 5 AEs occurring in 27 of 267 patients (10.1%) and 16 of 272 patients (5.9%) in each group, respectively.Conclusions and RelevanceIn the phase 3 SKYSCRAPER-06 randomized clinical trial, the primary end points were not met and the study has been terminated.Trial RegistrationClinicalTrials.gov Identifier: NCT04619797

Whole-body fluorodeoxyglucose positron emission tomography combined with computed tomography is widely used in cancer care, but manual lesion delineation is slow, subjective, and difficult to scale. We present GLOW-FDG, an open-source artificial intelligence model for whole-body cancer lesion segmentation in fluorodeoxyglucose positron emission tomography and computed tomography. The model was trained on 1,563 scans spanning multiple cancer types and evaluated on 185 external scans from independent institutions. Across breast cancer, nonmetastatic and oligometastatic lung cancer, head and neck cancer, and metastatic melanoma, GLOW-FDG consistently outperformed publicly available benchmark models in lesion detection, while reducing false positives and maintaining strong segmentation accuracy. Quantification of total tumor burden and total lesion glycolysis was robust across cohorts, and performance approached the variability observed between expert radiation oncologists. These results support GLOW-FDG as a generalizable tool for automated cancer segmentation and quantitative imaging biomarker extraction in whole-body imaging.

Importance:Programmed cell death 1 ligand 1/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, survival benefit is limited, and many patients experience disease progression. Objective:To evaluate the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC. Design, Setting, and Participants:SKYSCRAPER-06 was a phase 3 randomized clinical trial that recruited patients with previously untreated, locally advanced unresectable or metastatic NSCLC at 129 sites in 21 countries between December 15, 2020, and September 14, 2023 (data cutoff, April 19, 2024). Intervention:Patients were randomized 1:1 to receive either tiragolumab, 600 mg, plus atezolizumab, 1200 mg, plus chemotherapy (pemetrexed, 500 mg/m2, and carboplatin [area under the curve 5], or cisplatin, 75 mg/m2) or placebo plus pembrolizumab, 200 mg, plus chemotherapy via intravenous infusion on day 1 of each 21-day cycle until disease progression, loss of clinical benefit, unacceptable toxic effect, or withdrawal of consent. Main Outcomes and Measures:Primary end points were investigator-assessed progression-free survival and overall survival. The safety and tolerability of the study drugs were also evaluated. Results:Of 542 patients in the full analysis set (mean [SD] age, 63.6 [9.3] years; 353 [65.1%] male), 269 were randomized to tiragolumab plus atezolizumab plus chemotherapy and 273 to placebo plus pembrolizumab plus chemotherapy. Overall, baseline demographics were similar between treatment groups. At data cutoff (median follow-up, 11.8 months), median investigator-assessed progression-free survival was 8.3 months (95% CI, 7.1-9.6 months) with tiragolumab plus atezolizumab plus chemotherapy vs 9.9 months (95% CI, 8.7-11.9 months) with placebo plus pembrolizumab plus chemotherapy (hazard ratio, 1.27; 95% CI, 1.02-1.57; P = .99); median overall survival was 18.9 months (95% CI, 15.2-23.8 months) vs 23.1 months (95% CI, 20.7-33.0 months) in each treatment group, respectively (hazard ratio, 1.33; 95% CI, 1.02-1.73; P = .98). Grade 3 to 4 adverse events occurred in 164 of 267 patients (61.4%) in the tiragolumab plus atezolizumab plus chemotherapy group and 165 of 272 patients (60.7%) in the placebo plus pembrolizumab plus chemotherapy group, with grade 5 AEs occurring in 27 of 267 patients (10.1%) and 16 of 272 patients (5.9%) in each group, respectively. Conclusions and Relevance:In the phase 3 SKYSCRAPER-06 randomized clinical trial, the primary end points were not met and the study has been terminated. Trial Registration:ClinicalTrials.gov Identifier: NCT04619797.

BACKGROUND:The management of non-metastatic non-small-cell lung cancer (NSCLC) has become increasingly complex with the integration of multimodality strategies and biomarker-driven approaches. Several clinically relevant areas remain insufficiently defined by current evidence and international guidelines. We conducted an international multidisciplinary consensus to address major areas of uncertainty in real-world practice. METHODS:A modified Delphi process was conducted during a 3-day in-person meeting in Barcelona, Spain (3-5 September 2025). Eighty-nine thoracic oncology experts independently rated predefined clinical statements developed by working groups and refined by a steering committee. Agreement was assessed using a 9-point Likert scale. Consensus was predefined as ≥75% of ratings in the 7-9 range; rejection as ≥75% in the 1-3 range. RESULTS:Ninety-six statements were evaluated. Consensus was achieved for 62 statements (64%), 31 (32%) remained without consensus, and 3 (3%) were rejected. Consensus supported routine FDG PET-CT for staging, histologic confirmation of suspicious mediastinal nodes, reflex PD-L1 testing and DNA-based next-generation sequencing at diagnosis, standardized post-neoadjuvant pathologic assessment, and sublobar resection with systematic nodal evaluation for selected peripheral node-negative tumors ≤2 cm. Consolidation durvalumab after definitive chemoradiotherapy was supported irrespective of PD-L1 expression in unresectable stage II-III disease. Persistent areas of controversy included brain MRI in stage I disease, mediastinal restaging after induction therapy, routine RNA-based testing, and the use of circulating tumor DNA/minimal residual disease to guide perioperative decisions. CONCLUSIONS:This international consensus provides structured expert guidance in areas of uncertainty in non-metastatic NSCLC and highlights priorities for future prospective research.

Malignant Pleural Mesothelioma (MPM) is a rare cancer with limited treatment options. Large-scale deep biological description of intratumor heterogeneity at single-cell resolution is still missing. Recent studies of fresh tumor biopsies analyzed only a few patients, limiting resolution of population heterogeneity. To describe at single-cell resolution in FFPE tissues the cancer cell and tumor microenvironment heterogeneity of untreated MPM patients. Of the 400 enrolled patients in the BEAT-MESO clinical trial (NCT03762018), 220 patients had available tumor blocks for single-nuclei preparation. The study compared the chemotherapy and bevacizumab combination with and without atezolizumab (anti-PD-L) treatment. All patients signed the ICFs and approved the translational study. Single nuclei were prepared using the snPATHO protocol followed by 10x Genomics FLEX pipeline. Samples were sequenced on a Novaseq X platform. 179 of the available 220 samples had sufficient tumor content to perform the assay. In total, we detected 792’000 cells. We defined cell type identities using singleR with a combined reference map from non-small cell lung cancer (NSCLC) and a small mesothelioma cohort. We could readily identify cell types of the tumor microenvironment. The most abundant cell types beside tumor cells were cancer associated fibroblast/CAFS (median of 22% of all cells) and macrophages (14% of all cells). We could also define T cell heterogeneity, whereas CD4 TCM cells were the most abundant and detected in all patients, in contrast with proliferating CD4 or CD8 T cells which were absent in 68% of patients, suggestive of rich abundance of tumor reactive T cells. Among immune checkpoints, the expression of TIGIT was the highest, followed by LAG3 and PD1 expression. Tregs were rare and most frequently expressed TIGIT similar to CD8EM and CD4CM cells. We could also define an important heterogeneity of cancer-associated fibroblasts as well as of endothelial cells. Endothelial cell heterogeneity reflected on the proximity to B cells and tertiary lymphoid structures. In contrast, to previous single-cell RNA seq analysis of a small cohort of MPM, we could readily detect neutrophil granulocytes in the tumors. We will also provide data on matching H&E evaluation of TLSs. Depending on the maturation of clinical data, we will also present comparison with clinical parameters. Our results show the outstanding power to perform snRNAseq of fixed tissues from clinical trials. The method is readily compatible with large phase III clinical trials, and provide a much deeper insight into tumor heterogeneity than bulk RNAseq with deconvolution would do. Daria Buszta, Maxim Norkin, Jonathan Bac, Sanjay Popat, Anthony Pope, Riyaz Shah, Toby Talbot, Julia Giner, Wold-Dieter Janthur, Ernest Nadal, Annamaria Catino, David Gilligan, Amy Roy, Zoi Tsourti, Patrick Vagenknecht, Georgia Dimopoulou, Roswitha Kammler, Stephen P. Finn, Enriqueta Felip, Solange Peters, Rolf Stahel, Raphael Gottardo, Krisztian Homicsko. Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7147.

PURPOSE:CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with limited expression in normal tissues, making it an appealing target for innovative cancer immunotherapy approaches. Pleural mesothelioma (PM) is a highly aggressive disease with a need for new treatment options. Our objective was to investigate the expression of CD276 in the multicenter PM cohort of the European Thoracic Oncology Platform Mesoscape project and correlate the results with annotated clinical data. MATERIALS AND METHODS:Using tissue microarrays (TMAs), the expression of CD276, assessed using a semiquantitative aggregate H-score method on the membrane (and secondarily in the cytoplasm), was correlated with clinicopathologic characteristics and survival outcome. RESULTS:CD276 immunohistochemistry results were available for 353 patients, with mostly epithelioid histology (71%). Membranous CD276 expression was present in 86%. High membranous CD276 expression (H-score ≥the median H-score of 120) was significantly more common in females (P = .0029; 71% v 47%) and in epithelioid histology (P < .001; 59% v 29%), whereas no significant association in clinical outcome (overall survival [OS]/progression-free survival) was found. Cross-validation of the TMA method using whole sections revealed a moderate agreement for membranous assessment (Cohen's kappa = 0.47) and a lower agreement for cytoplasm assessment (Cohen's kappa = 0.37). In an exploratory analysis, high cytoplasmic CD276 expression was associated with worse prognosis (OS, log-rank P = .043), but was not significant when adjusting for other clinical variables. CONCLUSION:Although no prognostic value of CD276 expression was found, its high membranous expression (86%) in the PM samples of the study supports further research of its potential as a therapeutic target for this disease.

OBJECTIVE:To evaluate the addition of immunotherapy and metastasis-directed stereotactic body radiotherapy (SBRT) to induction chemotherapy followed by definitive local therapy of the locoregional primary tumour in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC). METHODS:CHESS is a prospective, international, multicentre, single-arm, phase II trial evaluating the efficacy and safety of combined chemotherapy (carboplatin plus paclitaxel), immune checkpoint inhibition (durvalumab) and metastasis-directed SBRT, followed by definitive radiotherapy or surgery of the primary tumour (if no disease progression at the 3-month restaging) and maintenance durvalumab for maximum one year in patients with synchronous oligometastatic NSCLC. The primary endpoint was one-year progression-free survival, aiming to an improvement from 25% to 50%. RESULTS:A total of 49 patients were enrolled from 11/2019 to 07/2022. Up to 05/2023, the median follow-up was 22 months. Of 47 patients starting treatment, 10 progressed and 2 died before restaging, while 35 proceeded to definitive therapy of the locoregional primary (11surgery, 24 radiotherapy). Among the first 42 evaluable patients, 14 (33%; ≥17 required) reached one year without progression, and the null hypothesis could not be rejected. The one-year overall survival rate for all patients was 74.9% (95% CI: 60.0%-84.9%). Treatment-related grade ≥ 3 adverse events were reported in 34% of patients, with no grade 5 event. CONCLUSION:The CHESS trial did not meet its primary endpoint. However, the favourable safety profile and promising overall survival provided the basis for further intensification of induction systemic therapy (addition of tremelimumab in a subsequent study cohort; CHESS-Cohort 2).

Background: ABC-lung explores the potential effect of combining atezolizumab and bevacizumab with either carboplatin/paclitaxel (ABCPac) or pemetrexed (ABPem) in patients with EGFR-mutant NSCLC, resistant to tyrosine kinase inhibitors (TKIs). Methods: ABC-lung is a 1:1 randomised, non-comparative, phase II trial, stratified by prior treatment with a thirdgeneration EGFR TKI, evaluating atezolizumab (1200 mg, Q3W) and bevacizumab (15mg/kg, Q3W) with either 4-6 cycles of carboplatin (AUC5, Q3W) and paclitaxel (175-200 mg/m2, Q3W) or pemetrexed (500 mg/m2, Q3W) until progression (PD). The study aimed to improve the 1-year progression-free survival (PFS) rate from 18% to 37%, assessed per RECISTv1.1, separately in each arm. To reject the null hypothesis, at least 14 of 45 evaluable patients in each arm needed to be progression-free at 1-year (power 83%, 1-sided a=0.023). Secondary

Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development. In breast cancer, several agents are already approved and widely used, including trastuzumab emtansine, T-DXd and SG, and multiple late-stage trials are ongoing. Thus, in the coming years, we are likely to see significant changes to treatment algorithms. As the number of available ADCs increases, biomarkers (of response and resistance) to better select patients are urgently needed. Biopsy sample collection at the time of treatment selection and incorporation of translational research into clinical trial designs are therefore critical. Biopsy samples taken peri- and post-ADC treatment combined with functional genomics screens could provide insights into response/resistance mechanisms as well as the impact of ADCs on tumour biology and the tumour microenvironment, which could improve understanding of the mechanisms underlying these complex molecules. Many ADCs are undergoing evaluation as combination therapy, but a high bar should be set to progress clinical evaluation of any ADC-based combination, particularly considering the high cost and potential toxicity implications. Efforts to optimise ADC dosing/duration, sequencing and the potential for ADC rechallenge are also important, especially considering sustainability aspects. The ETOP IBCSG Partners Foundation are driving strong collaborations in this field and promoting the generation/sharing of databases, repositories and registries to enable greater access data. This will allow the most important research questions to be identified and prioritised, which will ultimately accelerate progress and help to improve patient outcomes.

Supplementary Figure S8. Progression-free survival by EGFR del19/L858R mutational status at week 9 (N=105) - landmark analysis (post 9-week time).

8103 Background: The STIMULI clinical trial (NCT02046733) tested the combination of ipilimumab and nivolumab (IPI/NIVO) after standard chemoradiotherapy in patients with limited disease small cell lung cancer (LD-SCLC). The study showed no improvement in the primary endpoint of progression-free survival (PFS) in unselected patients. Accessing tumor samples is challenging in LD-SCLC after chemoradiotherapy; hence, we analyzed serum and whole blood RNA samples as biomarkers to stratify patients for clinical benefit. Methods: We used a semi-quantitative large-scale proteomic assay (SomaScan) to analyze more than 7000 proteins. We also profiled whole-blood RNA collected before and after chemoradiotherapy and performed Bulk RNA barcoding and sequencing (BRBseq). We analyzed 131 serum samples, of which one failed quality control. 119 whole blood Paxgene RNA before chemoradiotherapy and 124 after were also analyzed. We performed unsupervised hierarchical clustering on protein and RNA samples and defined differentially expressed proteins/transcripts and pathway enrichment in specific clusters. We also performed RNA deconvolution with CibersortX. In addition, we performed organ-specific aging prediction from serum proteomics using the orange Python pipeline. Results: We identified five patient proteotype clusters. Unexpectedly, the proteotypes corresponded to three types of clinical outcomes. Clusters 1, 3, and 4 were linked with a lack of benefit from immune therapy. Patients in cluster 2 had improved outcomes from immune therapy (HR: 0.436 CI: 0.1976 to 0.9078, p: 0.0272) and likely benefited most. In contrast, patients in cluster 5 had a decreased survival (HR: 5.53, CI: 1.261 to 24.28, p: 0.0234). These patients might represent a hyper-progression phenotype on immune therapy. Protein-based pathway analysis showed that cluster 1 patients had upregulated TGF𝛽, and IL-6 signaling, whereas patients in cluster 5 activated the complement pathway. In addition, preliminary analysis of organ aging showed that the patient clusters could also be linked with differential immune aging. Together, our prototypes suggest differential proteomic states of patients' underlying responses. In contrast with the protein data, RNA analysis did not lead to outcome predictors. We compared the protein signatures to single-cell RNAseq data of SCLC and found that these proteins might originate from the tumors. Conclusions: Proteotypes based on large-scale proteomic analysis could predict both the benefit and lack thereof for IPI/NIVO therapy in limited disease small cell lung cancer. The clusters also provide clues into differential pathway activation and could serve as potential new biomarkers and targets for precision adjuvant immune therapy of SCLC and beyond.

Supplementary Figure S5. Boxplot of EGFR T790M MAF distribution at baseline (N=136), week 9 (N=110) and progression (N=65) by treatment arm.

Supplementary Figure S10. Overall survival by EGFR T790M mutational status at week 9 (N=106) - landmark analysis (post 9-week time).

Supplementary Figure S4. Evolution of EGFR T790M mutational status across time for the N=45 patients with available samples at all 3 timepoints.

Purpose: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously.Experimental Design: Next-generation sequencing (Guardant360) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored, and molecular alterations at progression were described.Results: A total of 136 patients (88% of 155 randomized) had plasma samples at baseline (68 per arm), 110 (71%) at week 9, and 65 (42%) at progression. In a multivariable model for progression-free survival (PFS), the treatment effect was found to differ by smoking status (interaction P = 0.046), with the effect of smoking also differing by baseline EGFR T790M (interaction P = 0.033), whereas both TP53 at baseline and the tissue EGFR exon 21 L858R mutation were significantly associated with worse PFS outcome. Smokers (current/former) without baseline EGFR T790M showed a significant improvement in PFS under combination treatment, albeit with small numbers (P = 0.015). Week-9 EGFR T790M clearance was associated with improved PFS in the osimertinib arm (P = 0.0097). Acquired EGFR C797S mutations were detected in 22% and 13% of patients in the combination and osimertinib arms, respectively.Conclusions: The differential effect of treatment by smoking was not explained by TP53 mutations or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected, but no novel molecular alterations were identified in the combination arm.

Supplementary Figure S11. Overall survival by EGFR del19/L858R mutational status at week 9 (N=107) - landmark analysis (post 9-week time).

Supplementary Figure S6. Association of EGFR T790M MAF with time, based on N=136 baseline, N=110 week 9 and N=65 progression samples.